Emerging therapeutic approaches, such as CSF-1R inhibitors and immune-modulating agents, aim to reprogram TAMs to support anti-tumor immunity, facilitating the transition from a cold-to-hot tumor transition in BC [47, 48]. Here, CSF1R is linked to neoplasm.